|Day Low/High||6.14 / 6.42|
|52 Wk Low/High||3.26 / 11.35|
These promising companies look like good names for patient buy-and-hold investors.
Quotient Limited and Redhill Biopharma could deliver for shareholders, while Novavax Inc. and Inovio Pharmaceuticals may not in the end.
The trio consists of BioDelivery Sciences International, Beazer Homes USA and Redhill Biopharma.
Remembering these 'rules of the road' is vital in this highly volatile space.
Here's two 'rules of the road' when investing in this highly volatile space.
The Summit, N.J.-based firm said Thursday that it was discontinuing the GED-0301 (mongersen) Phase 3 Revolve study in Crohn's disease and the extension trial.
Companies developing drugs for cancer, eye problems and pets -- offer untapped value.
Redhill has some promising drugs in its pipeline, and is well funded.